Business, energy, technology, markets and global industry news from Business News Today

EHA 2026

PharmaDeviceNews EHA 2026
Representative image of advanced CAR T-cell therapy research and infusion monitoring, reflecting CARsgen Therapeutics’ CT0596 and CT1190B data in multiple myeloma and B-cell lymphoma.
Pharma & Biotech

How CARsgen’s EHA 2026 data could change investor debate around allogeneic CAR T

Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.

Read More
Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.
Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More
Representative image of a clinical oncology research setting as PeproMene Bio’s PMB-CT01 BAFF-R CAR T data highlight a potential new treatment path for relapsed B-cell lymphoma after CD19 CAR T failure.
Pharma & Biotech

PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma

PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.

Read More
Representative image: A hematology researcher reviews blood sample data in a clinical laboratory, reflecting PharmaEssentia’s new ropeginterferon alfa-2b evidence in essential thrombocythemia ahead of ASCO 2026 and EHA 2026.
Pharma & Biotech

Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?

PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.

Read More